Consistent with our in vitro data (Fig. 4E, S7C), FGFR inhibitors erdafitinib and infigratinib, and EGFR inhibitor gefitinib, enhanced alectinib sensitivity, delaying tumor remissions (Fig. 5C, D, S8B–D). Here, EGFR is linked to neoplasm.